Effect of latanoprost on intraocular pressure in patients with glaucoma on maximal tolerated medical treatment
Open Access
- 1 December 1997
- journal article
- other
- Published by BMJ in British Journal of Ophthalmology
- Vol. 81 (12) , 1115b
- https://doi.org/10.1136/bjo.81.12.1115b
Abstract
Editor,—Latanoprost 0.005% is a prostaglandin analogue that causes reduction of the intraocular pressure (IOP) by increasing the uveoscleral outflow of aqueous humour through the ciliary muscle region to the suprachoroidal space and the episcleral veins.12 Initial studies on latanoprost demonstrated reductions of 20% to 40% in the IOP of normotensive volunteers, patients with ocular hypertension, and glaucoma patients.3-10 The efficacy of latanoprost 0.005% in lowering the intraocular pressure (IOP) in different glaucoma populations, especially when added to anti-glaucoma medications already being used, …Keywords
This publication has 7 references indexed in Scilit:
- Around-the-Clock Intraocular Pressure Reduction With Once-Daily Application of Latanoprost by Itself or in Combination With TimololArchives of Ophthalmology (1950), 1996
- Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol.British Journal of Ophthalmology, 1995
- The Effects on Aqueous Dynamics of PhXA41, a New Prostaglandin F2α Analogue, After Topical Application in Normal and Ocular Hypertensive Human EyesArchives of Ophthalmology (1950), 1993
- Interaction of PhXA41, a New Prostaglandin Analogue, With PilocarpineArchives of Ophthalmology (1950), 1993
- Maintained Intraocular Pressure Reduction With Once-a-Day Application of a New Prostaglandin F2α Analogue (PhXA41)Archives of Ophthalmology (1950), 1993
- Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2α-1-isopropylester in the cynomolgus monkeyExperimental Eye Research, 1989
- Reduction of intraocular pressure in normal and glaucomatous primate (Aotus trivirgatus) eyes by topically applied prostaglandin F2αCurrent Eye Research, 1981